Education
About Us
Working with TipRanks
Follow Us
National Research Corp (NRC)
NASDAQ:NRC
Top Page
National Research
(NASDAQ:NRC)
66Neutral
National Research (NRC) vs. S&P 500 (SPY)
Market Cap
$349.56M
Dividend Yield3.16%
Average Volume (3M)96.40K
Price to Earnings (P/E)14.6
Beta (1Y)0.58
Revenue Growth-3.72%
EPS Growth-17.12%
CountryUS
Employees435
SectorHealthcare
Sector Strength78
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)1.04
Shares Outstanding23,476,040
10 Day Avg. Volume126,412
30 Day Avg. Volume96,401
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.48
Price to Cash Flow (P/CF)9.50
P/FCF Ratio11.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
National Research Business Overview & Revenue Model
Company DescriptionNational Research Corporation (NRC) is a leading provider of analytics and insights for the healthcare industry. The company specializes in patient experience and customer satisfaction data, offering healthcare organizations valuable feedback and performance metrics. NRC's core products and services include survey solutions, analytics platforms, and consulting services designed to enhance patient-centered care and improve organizational outcomes.
How the Company Makes MoneyNRC makes money primarily through its subscription-based revenue model, where healthcare providers, including hospitals and clinics, pay for access to its data analytics platforms and survey tools. These subscriptions provide clients with ongoing insights into patient experience and satisfaction metrics. Additionally, NRC generates revenue through consulting services, where it offers expertise to help healthcare organizations interpret data and implement strategies for improvement. Key partnerships with healthcare institutions and continuous innovation in data analytics contribute significantly to NRC's earnings.
National Research Financial Statement Overview
Summary
National Research exhibits stable revenue growth and profitability in the healthcare sector. The balance sheet shows increased leverage, which may pose a risk if not managed carefully. However, strong cash flow generation provides a cushion for financial flexibility. The company is well-positioned but should focus on improving equity returns and managing debt levels.Income Statement
The company has shown moderate revenue growth with some fluctuations over the years. The gross profit margin is strong, indicating efficient cost management. However, there is a slight decline in net income, impacting the net profit margin. Overall, the company maintains healthy profitability with consistent EBIT and EBITDA margins.72
Positive
Balance Sheet
The balance sheet reflects a stable equity base, though there is a noticeable increase in total debt, leading to a higher debt-to-equity ratio. The return on equity has decreased year over year due to lower net income and reduced equity. The company maintains a reasonable equity ratio, indicating a balanced asset funding structure.65
Positive
Cash Flow
Operating cash flow is strong, with a positive operating cash flow to net income ratio, indicating efficient cash generation. Free cash flow growth is positive, suggesting good cash management despite some variability in capital expenditures. The cash flow metrics are generally favorable, highlighting effective cash utilization.78
Positive
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 144.15M | 148.58M | 151.57M | 147.95M | 133.28M | 127.98M | Gross Profit |
| 83.39M | 92.56M | 94.52M | 95.60M | 84.09M | 81.55M | EBIT |
| 37.35M | 40.05M | 46.54M | 50.27M | 42.68M | 43.03M | EBITDA |
| 43.30M | 45.98M | 51.83M | 56.66M | 50.78M | 48.15M | Net Income Common Stockholders |
| 27.08M | 30.97M | 31.80M | 37.47M | 37.26M | 32.41M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.99M | 6.65M | 25.03M | 54.36M | 34.69M | 13.52M | Total Assets |
| 107.68M | 122.44M | 130.46M | 157.54M | 133.42M | 110.69M | Total Debt |
| 3.67M | 38.96M | 22.18M | 26.55M | 30.61M | 34.17M | Net Debt |
| -9.32M | 32.30M | -2.85M | -27.81M | -4.08M | 20.66M | Total Liabilities |
| 88.60M | 73.48M | 58.43M | 72.20M | 69.11M | 77.79M | Stockholders Equity |
| 19.08M | 48.95M | 72.03M | 85.34M | 64.31M | 32.89M |
| Cash Flow | Free Cash Flow | ||||
| 25.18M | 22.33M | 26.43M | 40.83M | 36.65M | 36.26M | Operating Cash Flow |
| 39.95M | 38.11M | 36.27M | 46.34M | 40.64M | 40.92M | Investing Cash Flow |
| -19.61M | -15.78M | -9.84M | -8.51M | -3.72M | -4.66M | Financing Cash Flow |
| -20.71M | -40.71M | -55.58M | -18.16M | -15.50M | -36.35M |
National Research Technical Analysis
Negative
14.89
Price Trends
16.62
Negative
17.70
Negative
20.36
Negative
Market Momentum
-0.65
Negative
40.24
Neutral
62.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRC, the sentiment is Negative. The current price of 14.89 is below the 20-day moving average (MA) of 15.70, below the 50-day MA of 16.62, and below the 200-day MA of 20.36, indicating a bearish trend. The MACD of -0.65 indicates Negative momentum. The RSI at 40.24 is Neutral, neither overbought nor oversold. The STOCH value of 62.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRC.
National Research Risk Analysis
National Research disclosed 21 risk factors in its most recent earnings report. National Research reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
National Research Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $960.81M | 50.12 | 5.72% | 0.34% | 4.51% | 32.28% | |
66 Neutral | $349.56M | 14.62 | 61.77% | 3.16% | -3.72% | -17.12% | |
63 Neutral | $1.67B | 16.39 | 1.76% | 4.52% | -10.24% | -106.48% | |
60 Neutral | $1.67B | 136.14 | 1.03% | ― | -3.04% | ― | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% |
* Healthcare Sector Average
Performance Comparison
NRC
National Research
14.89
-24.37
-62.07%
HSTM
HealthStream
30.98
4.99
19.20%
OMCL
Omnicell
35.71
7.95
28.64%
PINC
Premier
18.34
-1.80
-8.94%
National Research Earnings Call Summary
Earnings Call Date: Jan 27, 2025 | % Change Since: -20.50% | Next Earnings Date: May 6, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted the company's strategic plans to expand its market and integrate innovative AI solutions, with positive organizational changes and financial management. However, financial results were flat year-over-year, and there is an expectation of increased net debt due to ongoing investments.Highlights
Expansion Goals and Strategy
The company aims to double the total addressable market through portfolio additions, acquisitions, and partnerships, with a focus on double-digit annual revenue growth and expanding margins.
Organizational and Leadership Changes
The company has restructured its leadership and sales teams, adding new leaders and sales associates, and implemented new compensation plans and training programs to accelerate pipeline growth.
Innovative Technology and AI Integration
Investment in AI and product leadership to deliver innovative AI solutions to clients, with new tools and insights expected soon in the market.
Financial Management and Capital Allocation
Operating cash flows increased to $12 million compared to $8 million in the previous year. The company returned $18 million to stockholders through dividends and stock repurchases.
Lowlights
Flat Year-over-Year Financial Results
The financial results were consistent with expectations but relatively flat year-over-year, indicating no significant revenue growth in the short term.
Increased Net Debt
Net debt is expected to increase over the balance of the year due to ongoing investments in technology and market expansion.
Company Guidance
During National Research Corporation's Q1 2024 earnings call, the company outlined ambitious financial goals, including doubling their total addressable market through strategic portfolio additions, acquisitions, and partnerships, and achieving double-digit annual revenue growth. The company aims to expand its margins and create significant value for investors by leveraging its health care DNA and innovative technologies. With plans to enhance enterprise-wide experience solutions and apply a generative AI overlay across their offerings, NRC is focused on providing actionable insights that improve client revenue and costs. Despite flat financial results year-over-year, operating cash flows increased from $8 million to $12 million compared to the previous year, with $18 million returned to stockholders through dividends and stock repurchases. The company maintains a net debt of $40 million as of March 31, 2024, and plans to continue funding growth investments while ensuring financial flexibility for future opportunities.National Research Corporate Events
Stock BuybackDividendsFinancial Disclosures
National Research Reports Decline in Q4 2024 Revenue
Negative
Jan 27, 2025
National Research Corporation reported a decrease in revenue and earnings for the fourth quarter of 2024 compared to the same period in 2023. The company returned $10.1 million to shareholders through dividends and stock repurchases, indicating a strategic focus on delivering value to stakeholders despite financial challenges.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.